HEALTH● LOWJun 26 · Jun 26, 2026, 1:59 PM
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
Seeking Alpha Tech
Capricor's stock has decreased in value following the FDA's announcement of an Advisory Committee meeting to review its Duchenne therapy. This signals a key regulatory step for the potential treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH45m agoEbola: Africa CDC mourns as DRC doctor dies from virusPremium TimesHEALTH1h agoWhich vaccinations should you have this autumn and which are recommended in GermanyEuroNews [en]HEALTH1h agoScientists confirm fruit and vegetable skin really is good for youNew ScientistHEALTH1h agoNipah medicine row: Action after receiving expert panel report, says Keralam Health MinisterThe Hindu